Gliclazide is an oral anti-diabetic (hypoglycemic) drug which is classified as a sulfonylurea and is indicated for the control of hyperglycemia in gliclazide-responsive diabetes of stable, mild, non-ketosis prone, maturity-onset or adult type.
The drug is used when proper dietary adjustment and exercise fail to reduce the blood sugar content or for conditions that are not suitable for insulin therapy.
The approval and production license issuance brought Tianyin’s portfolio to 58 products in total, 24 of which are reimbursed by China’s Government Medical Insurance Program.